Purpose: Cardiac carcinoma is the most common subtype of gastric cancer and its incidence has increased in recent years. e current chemotherapeutic drugs exhibit limited e ectiveness and signi cant side e ects in patients. Maslinic acid (MA) exerts an antitumor activity on a wide range of cancers and has no signi cant side e ect; however, the anti-tumor e ect of MA on cardiac carcinoma has not yet been explored.Methods: MTT assays, tumor xenogra animal model, immunoblotting, MMP assessment and ow cytometry were performed in this study.Results: MA was able to suppress the viability of cardiac carcinoma cells in both a timeand dose-dependent manner. is natural compound exhibited no cytotoxicity in normal cells. Its inhibitory e ect on tumor growth was further con rmed in a mouse model. Mechanistically, MA induced the activation of p38 MAPK in cardiac carcinoma cells and, in turn, changed their mitochondrial membrane potential (MMP). Finally, caspase cascades were activated by a series of cleavages, leading to apoptosis in cardiac cancer cells. Inhibition of p38 MAPK signaling was able to rescue the e ect of MA on cardiac carcinoma cells.
Conclusion:Our data demonstrated that natural compound, MA, suppressed the growth of cardiac carcinoma by inducing apoptosis via the p38 MAPK/mitochondria/caspase pathway. MA and its derivatives may be promising anti-tumor agents for cardiac carcinoma treatment in the future.